（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS ...
Source Link（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.